Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 167Neoplasms 30Neoplasm Metastasis 29Brain Neoplasms 16Breast Neoplasms, Male 15Head and Neck Neoplasms 8Urinary Bladder Neoplasms 7Stomach Neoplasms 7Squamous Cell Carcinoma of Head and Neck 6Ovarian Neoplasms 6Colorectal Neoplasms 6Prostatic Neoplasms 5Inflammatory Breast Neoplasms 5Glioblastoma 5Carcinoma, Non-Small-Cell Lung 5Esophageal Neoplasms 4Carcinoma, Ovarian Epithelial 4Unspecified Adult Solid Tumor, Protocol Specific 3Salivary Gland Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Lung Neoplasms 3Gliosarcoma 3Glioma 3Gallbladder Neoplasms 3Ependymoma 3Carcinoma, Squamous Cell 3Triple Negative Breast Neoplasms 2Solid Tumors 2Osteitis Deformans 2

Interventions

ganitumab 3Paclitaxel 23-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 2tislelizumab 1teprotumumab 1dalotuzumab 1conatumumab 1cixutumumab 1Sorafenib 1Receptor Protein-Tyrosine Kinases 1Lapatinib 1Istiratumab 1Cisplatin 1Carboplatin 1Capecitabine 1BIIB022 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Insulin-Like Growth Factor I, Resistance To × Lapatinib × Clear all
NCT00684983 2020-03-24

Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
64 enrolled 13 charts
Breast

Insulin-Like Growth Factor I, Resistance To, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡